Stockreport

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences, Inc.  (COGT) 
Last cogent biosciences, inc. earnings: 11/8 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.cogint.com/investor-relations
PDF -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% p [Read more]